Henry Ford Health System recruits volunteers to obtain COVID-19 vaccines developed through Moderna.
The Detroit-based health care formula is one of 90 sites in the country and the only Michigan site that will offer the drug during Phase 3, according to a statement released Tuesday through the Henry Ford Health System. Researchers hope to recruit 30,000 volunteers across the country to get the vaccine, which is given through two injections.
Moderna is preparing the vaccine in partnership with the National Institutes of Health. Across the country, more than 150 coronavirus vaccines are being developed, 20 of which are in clinical trials.
“We are in an unprecedented period,” said Dr. Marcus Zervos, head of Henry Ford Health’s Division of Infectious Diseases. “COVID-19 causes millions of infections, thousands of deaths and the vaccine is our most productive hope for resolving the infection.”
Participants in the double-blind exam will have a 50% chance of receiving a placebo of the vaccine, which, unlike other vaccines, does not involve the actual virus, according to the hospital system.
Instead, the mRN vaccine, a genetic code that triggers the production of a protein intended to help the immune formula produce antibodies opposed to the virus.
Trial participants must be over 18 years of age and free from diseases or situations that compromise the immune system.
Those wanted for the trial come with others with the greatest threat of exposure to the virus, others over the age of 65 at risk of a severe case of the virus and others with “stable pre-existing medical situations at that time of screening.” Array”
Each player will get $1,000 if they make all visits.
People who have already had COVID-19 are eligible for the study, Zervos said.
“We work with teams to make sure our inclusion is representative of our patient population and also of our community,” he said.
Individuals can volunteer at www.henryford.com/ModernaVaccine and, if contacted through the hospital, can register in Detroit for the Henry Ford Hospital Emergency Department on the seventh floor of the New Center One Building or paH Employee Health Clinic.
Participants will receive two injections approximately 28 days apart, the registration center approximately seven times and will speak with the exam organizers approximately once a month for two years.
Researchers will monitor Americans for symptoms of COVID-19 or the antibodies the vaccine will produce.
“If a player is diagnosed with COVID-19 during his time on the exam, the test team will provide the highest point of care,” the hospital formula said in a statement.
Recruiting volunteers comes when President Donald Trump once re-sold hydroxychloroquine, an antimalarial drug, as an effective treatment. While several studies have found it ineffective, a Henry Ford Health published in early July found that the drug “significantly” reduced the mortality rate of patients involved in the analysis.
Zervos, who helped lead the Henry Ford Health study, suggested more studies to see if hydroxychloroquine works with COVID-19.
More than six hundred more people participated in the first two stages of the Modern Vaccine trial. The first phase decided that the drug was safe and the moment phase showed that the framework produced antibodies in reaction to the vaccine.
In the third phase, researchers will determine whether antibodies effectively prevent others from contracting the virus.
The side effects experienced by the participants come with arm pain, redness or short-lived low-intensity fever, Zervos said.